Position statement on radiopharmaceutical production for clinical trials

G. Bormans, A. Buck, A. Chiti, M. Cooper, J. Croasdale, M. Desruet, V. Kumar, Y. Liu, I. Penuelas, C. Rossetti, R. Schiavo, S. W. Schwarz, A. D. Windhorst

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


The EU regulation 536/2014 aims to facilitate the experimental use of diagnostic radiopharmaceuticals in particular for GMP requirements and needs to be applied in EU countries. As definitely clarified by this survey, the application is still far from being completed due to national restrictions that are conflicting with the content of the above EU regulation. Although the nuclear medicine centers are obliged to be compliant with national regulatory, national authorities have to be required to work towards full application of the regulation. On the other hand, an update of 536/2014 that includes therapeutic radiopharmaceuticals would also be beneficial to a rational and safe advance of nuclear medicine.

Original languageEnglish
Article number12
JournalEJNMMI Radiopharmacy and Chemistry
Issue number1
StatePublished - Dec 1 2017


  • Clinical trials
  • Radiopharmaceuticals
  • Regulatory


Dive into the research topics of 'Position statement on radiopharmaceutical production for clinical trials'. Together they form a unique fingerprint.

Cite this